Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 4/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CASP2 | P42575 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20380968 | 0.86 | ALDH1A1 (0.44) | ALDH1A1ESR1GAACASP2CNR1 | |
| SCHEMBL20362595 | 0.81 | CASP2 (0.47) | ALDH1A1GAACASP2HPGD | |
| SCHEMBL19776395 | 0.80 | SIGMAR1 (0.37) | ALDH1A1GAACASP2HPGD | |
| SCHEMBL23126135 | 0.78 | FAAH (0.45) | ALDH1A1GAACASP2CNR1 | |
| SCHEMBL19245438 | 0.78 | SMN1; SMN2 (0.41) | ALDH1A1GAAHPGD | |
| SCHEMBL20143551 | 0.78 | ALDH1A1 (0.34) | ALDH1A1GAACASP2 | |
| SCHEMBL17662624 | 0.78 | HTT (0.38) | ALDH1A1GAACNR1 | |
| SCHEMBL25896444 | 0.77 | MEN1 (0.48) | — | |
| SCHEMBL26618323 | 0.77 | GAA (0.33) | ALDH1A1GAACASP2 | |
| SCHEMBL26034556 | 0.77 | ALDH1A1 (0.38) | ALDH1A1GAACASP2CNR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | ALDH1A1 1330/4885ESR1 4650/4885GAA 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.